| 1 |
CR1L, complement component 3b/4b receptor 1-like |
Cell movement of leukocytes |
ALDOA, APOA1, BGN, C3, CD9, CNN1, COL18A1, COL1A1, COL4A1, CRYAB, DCN, FN1, GSN, HSPD1, ITGA5, ITGB1, LUM, MCAM, MYH11, MYL9, PFN1, SERPINA1, SERPINA3, SERPINE1, SERPINF1, Tpm2, YBX1 |
| HTT, huntingtin |
Formation of epithelial tissue |
| INHA, inhibin alpha |
Muscle contraction |
| ITGA2, integrin subunit alpha 2 |
|
| 2 |
CR1L, complement component 3b/4b receptor 1-like |
Advanced stage solid tumor |
COL18A1, COL4A1, COL6A3, FN1, NID2, SERPINE1 |
| SMAD7, SMAD family member 7 |
Metastatic solid tumor |
| 3 |
HNF1B, HNF1 homeobox B |
Cellular infiltration by leukocytes |
APOA1, BGN, CRYAB, DCN, FGB, FN1, HSPD1, ITGB1, MCAM, SERPINA1, SPARC, YBX1 |
| HTT, huntingtin |
|
| ITGA2, integrin subunit alpha 2 |
|
| PDGF (family), platelet derived growth factor |
|
| 4 |
APP, amyloid beta precursor protein |
Cell movement of sarcoma cell lines |
CTSB, FN1, SERPINE1, SERPINF1, SOD2, STMN1, VCP |
| NFE2L2, nuclear factor, erythroid 2 like 2 |
|
| 5 |
ANGPT2, angiopoietin 2 |
Anemia |
ANXA1, APOE, C3, C4A/C4B, CFB, CP, CRP, FN1, HBB, LGALS3, PRDX1, PRDX2, PRDX3, RPS6, SOD1, SOD2, TF |
| GH1, growth hormone 1 |
| Phenylbutazone |
|
| Prednisolone |
|
| 6 |
miR-122–5p (miRNAs w/seed GGAGUGU) |
Carcinoma in lung |
ALDOA, GPX7, P4HB, PKM, PRDX2, VIM |
|
|
Cell viability of tumor cell lines |
|
| 7 |
HNF1B, HNF1 homeobox B |
Cell movement of neutrophils |
ALB, BGN, FGB, FN1, LUM, SERPINA1, SPARC |
|
|
Cellular infiltration by leukocytes |
|
| 8 |
ANGPT2, angiopoietin 2 |
Endoplasmic reticulum stress response |
CALR, DNAJB4, HSP90AB1, HSPA5, HSPD1, SERPINH1, SOD1 |
| Tanespimycin |
|
| 9 |
INSR, insulin receptor |
Proliferation of muscle cells |
CTSB, FHL1, FN1, HSPD1, ITGA5, OGN, SERPINE1, VTN |
| ITGAV, integrin subunit alpha V |
|
| 10 |
Phenylbutazone |
Anemia |
ANXA1, ANXA2, C4A/C4B, CP, FGB, LGALS3 |
|
|
Hemostasis |
|